AKT1 and metabolic dysfunction-associated steatotic liver disease: To explore the effects of hepatic ChREBP loss on the progressive development of NAFLD in HFD-induced mice, the expression of AKT/mTOR, glycolysis, de novo lipogenesis, and insulin signaling pathway candidates was investigated with immunohistochemical staining.